Landmark deal paves way for cheaper HIV protection jab

The article discusses a landmark deal that has paved the way for a cheaper HIV protection injection in developing countries. The drug, which is administered twice a year, can significantly reduce the cost of current HIV treatment in these regions. The agreement, reached between the pharmaceutical company and global health organizations, aims to make the injectable HIV prevention treatment more accessible to people in low- and middle-income countries. This is seen as a significant step forward in the fight against HIV/AIDS, as the new injection is expected to be more affordable and convenient than existing oral treatments. The article highlights the potential impact of this deal, which could help expand access to HIV prevention and improve health outcomes for vulnerable populations. It emphasizes the importance of collaborations between pharmaceutical companies and global health organizations in addressing the HIV/AIDS epidemic, particularly in resource-limited settings.